Ad
ECYT News and Press Endocyte Inc.
-
Clovis, a "trading stock," has some shakiness in its fundamentals. Moreover, the shares tend to rise and fall for you to trade for short-term gains. Due to upcoming catalysts in June, Clovis is a trading stock that is about to embark on another bullish cycle. Despite being a tradi...
-
I have been hesitant about buying into Progenics Pharmaceuticals ( PGNX ) due to my insufficient knowledge about the advancements of radiopharmaceuticals in the oncology arena. Perhaps it is all the hype of immuno-oncology and the rise of gene therapy that caused me to believe that radiopharma...
-
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look ...
-
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. There are two monster meetings on the agenda next week that could shake things up f...
-
Endocyte (NASDAQ: ECYT ) Q3 results ($M): Net loss: (23.3) ( -84.9%). More news on: Endocyte, Inc., Novartis AG, Healthcare stocks news, Earnings news and commentary, Read more ...
-
Entered into agreement and plan of merger with Novartis AG for $2.1Billion WEST LAFAYETTE, Ind., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics...
-
There are 66 stocks in the Russell 3,000 that are up more than 100% year-to-date in 2018. Below is a list of the 40 best performers. As shown, three stocks - NII Holdings (NIHD), Tandem Diabetes (TNDM), and Turtle Beach (HEAR) - are up 1,000%+ year-to-date, meaning they've recorded "10-baggers...
-
Biotech Pulse Biotechnology is in a Bear Market. At least the midcap and smallcap segment of it. The S&P Biotechnology Select Index ( XBI ), which is weighted towards the midcap and smallcap companies, has dropped 24% from its high recorded on August 30 to its lowest point past Monda...
-
WEST LAFAYETTE, Ind., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at two upcoming investor conferences ...
Stock Information
Get ECYT Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
